Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 42

NCT ID: NCT00005960 Active, not recruiting - Prostate Cancer Clinical Trials

Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Start date: October 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have prostate cancer that has not responded to hormone therapy.

NCT ID: NCT00005939 Active, not recruiting - Prostate Cancer Clinical Trials

Brachytherapy in Treating Patients With Recurrent Prostate Cancer

Start date: November 1999
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy radiation to damage tumor cells. Brachytherapy uses radioactive material that is placed directly into or near the tumor. Brachytherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of brachytherapy in treating patients who have recurrent prostate cancer that has not responded to standard therapy.

NCT ID: NCT00003915 Active, not recruiting - Prostate Cancer Clinical Trials

Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer

Start date: May 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using bicalutamide and leuprolide may fight prostate cancer by reducing the production of androgens. PURPOSE: Phase II trial to study the effectiveness of chemotherapy consisting of docetaxel and estramustine plus hormone therapy in treating patients who have previously undergone radiation therapy or surgical removal of the prostate for stage I prostate cancer.

NCT ID: NCT00003734 Active, not recruiting - Prostate Cancer Clinical Trials

Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer

Start date: December 1998
Phase: Phase 3
Study type: Interventional

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin and flutamide may fight cancer by reducing the production of androgens. It is not yet known whether giving hormone therapy for 4 months is more effective than giving therapy for 8 months prior to radiation therapy for prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of combination hormone therapy for 4 or 8 months followed by radiation therapy in treating patients with prostate cancer.

NCT ID: NCT00003717 Active, not recruiting - Prostate Cancer Clinical Trials

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Start date: October 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than once drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel plus estramustine in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.

NCT ID: NCT00003633 Active, not recruiting - Prostate Cancer Clinical Trials

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

Start date: August 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of combination chemotherapy in treating patients with advanced prostate cancer.

NCT ID: NCT00003183 Active, not recruiting - Prostate Cancer Clinical Trials

Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer

Start date: March 1997
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more sensitive to the chemotherapy drug and may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of mitoxantrone plus G-CSF in treating patients with metastatic prostate cancer that has not responded to hormone therapy.

NCT ID: NCT00002775 Active, not recruiting - Prostate Cancer Clinical Trials

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Start date: February 1998
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel and estramustine in treating patients who have metastatic prostate cancer.